Dr Robert Giugliano
Disclosure details
Clinical trials / Research support:1. Amgen
2. Anthos Therapeutics
3. Daiichi Sankyo
4. Ionis
Honoraria for Lectures / CME Programs:
1. Academic CME
2. Amgen
3. Centrix
4. Daiichi Sankyo
5. Dr. Reddy’s Laboratories
6. Medical Education Resources (MER)
7. Medscape
8. Menarini
9. Merck
10. Pfizer
11. SAJA Pharmaceuticals
12. Servier
13. Shanghai Medical Telescope
14. SUMMEET
15. Voxmedia
Consultant: 1. Amarin
2. Amgen
3. Artivion, Inc.
4. Bayer
5. Beckman Coulter
6. Boston Scientific
7. Caladrius
8. CSL Behring
9. CVS Caremark
10. Daiichi Sankyo
11. Esperion
12. Gilead
13. Hengrui
14. Inari
15. Janssen
16. Novartis
17. Paratek
18. Pfizer
19. PhaseBio Pharmaceuticals
20. Samsung
Professor of Medicine | Harvard Medical School
Senior Investigator, TIMI Study Group | Cardiovascular Division, Brigham and Women’s Hospital, Boston
Dr Robert P. Giugliano is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude and phi beta kappa from Dartmouth College, and received his medical degree at Harvard Medical School. Dr Giugliano completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital, USA.
His research interests include novel lipid-lowering therapies, antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), and the assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 350 original articles and 250 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology.
Dr Giugliano is the Principal TIMI Investigator for over a dozen clinical trials including the VESALIUS-CV trial with evolocumab, ENGAGE AF-TIMI 48 trial with edoxaban, and Executive Committee member of several additional trials including the IMPROVE-IT (ezetimibe), FOURIER (evolocumab), AZALEA-TIMI 71 (abelacimab) and CORE trials (olezarsen) trials.
